Mechanism of action of the drug aspirin. Aspirin works by stopping prostaglandin being made: aspirin molecules (blue hexagons) enter the cell and chemically modify the cyclooxygenase enzyme (purple) to prevent prostaglandin being made. Unlike most prostaglandin, which are produced by glands and prostaglandin in prostaglandin bloodstream to act on distant areas of the body, the prostaglandins are produced at the site where they are needed.

Prostaglandins are produced in nearly all cells and are part of the body’s way of dealing with injury and illness. Prostaglandins act as signals to control several different processes depending on the part of the body in which they are made. Prostaglandins are made at sites of tissue damage or infection, where they cause inflammation, pain and fever as part prostaglandin the healing process.

When a blood vessel is injured, a prostaglandin called thromboxane stimulates the formation of a blood clot to try to heal the damage; it also causes the muscle in the blood vessel wall to contract (causing the blood vessel to narrow) to try to prevent blood loss.

Another prostaglandin called prostacyclin has the opposite effect to thromboxane, reducing blood clotting and removing any clots that are no prostaglandin needed; it also causes the muscle in the blood vessel wall to relax, so that the vessel dilates. The opposing effects that thromboxane and prostacyclin have on the width of blood vessels can control the amount of blood flow and regulate response to injury and inflammation. Prostaglandins are also involved in regulating the contraction and relaxation of the muscles in the gut and the airways.

Prostaglandins are known to regulate the female reproductive prostaglandin, and are involved in the control of ovulation, the menstrual cycle and the induction of labour.

Indeed, manufactured forms of prostaglandins - most commonly prostaglandin E 2 - can be used to induce (kick-start) labour.

How are prostaglandins controlled? The chemical reaction that makes the prostaglandins involves several steps; the first step is carried out by an enzyme called cyclooxygenase.

There are two main types of this enzyme: cyclooxygenase-1 and cyclooxygenase-2. When the body is functioning normally, baseline levels of prostaglandins are produced by the action of cyclooxygenase-1. When the body is injured (or inflammation occurs in any area of the body), cyclooxygenase-2 is activated and produces extra prostaglandins, which help the body to respond to the injury.


Prostaglandins carry out their actions by acting on specific receptors; at least eight different prostaglandin receptors have been discovered.

The presence of these receptors in different organs throughout the body allows the different actions of each prostaglandin to be carried out, depending on which receptor they interact with.

Prostaglandins are very short-lived and are broken down quickly by the body. They only carry out their actions in the immediate vicinity of where they are produced; this helps to regulate and limit their actions. What happens if my levels of prostaglandins are too high?

High levels of prostaglandins are produced in response to injury or infection prostaglandin cause inflammation, which is associated with the symptoms of redness, swelling, pain and fever. This is an important part of the body’s normal healing process. However, this natural response can sometimes lead to excess and chronic production of prostaglandins, which may contribute to several diseases by causing unwanted inflammation.

This means that drugs, which specifically block cyclooxygenase-2, can be used to treat conditions such as arthritis, heavy menstrual bleeding and painful menstrual cramps. There is also evidence to suggest that these drugs may have a beneficial effect when treating certain types of cancer, including colon and breast cancer, however research in this area is still ongoing. New discoveries are being made about cyclooxygenases which suggest that cyclooxygenase-2 is not just responsible for disease but has other functions.

Anti-inflammatory drugs, such as aspirin and ibuprofen, work by blocking the action of the cyclooxygenase enzymes and so reduce prostaglandin levels. Prostaglandin is how these drugs work to relieve the symptoms of inflammation. Aspirin prostaglandin blocks the production of thromboxane and so can be used to prevent unwanted blood clotting in patients with heart disease.

What happens if my levels prostaglandin prostaglandins prostaglandin too low? Manufactured prostaglandins can be used to increase prostaglandin levels in the body under certain circumstances. For example, administration of prostaglandins can induce labour at the end of pregnancy or abortion in the case of an unwanted pregnancy.

They can also be used to treat stomach ulcers, glaucoma and congenital heart disease in newborn babies. Further advances in understanding how prostaglandins work may lead to newer treatments for a number of conditions.

Last reviewed: Oct 2019 I 2 - Prostacyclin The prostaglandins ( PG) are a group of physiologically active lipid compounds called eicosanoids [1] having diverse hormone-like effects in animals. Prostaglandins have been found in almost every tissue in humans and other animals. They are derived enzymatically from the fatty acid arachidonic acid. [2] Every prostaglandin contains 20 carbon atoms, including a 5-carbon ring. They are a subclass of eicosanoids and prostaglandin the prostanoid class of fatty acid derivatives.


The structural differences between prostaglandins account for their different biological activities. A given prostaglandin may have different and even opposite effects in different tissues in some cases. The ability of the prostaglandin prostaglandin to stimulate a reaction in one tissue and inhibit the same reaction in another tissue is determined by the type of receptor to which the prostaglandin binds.

They act as autocrine or paracrine factors with their target cells present in the immediate vicinity of the site of their secretion. Prostaglandins differ from endocrine hormones in that they are not produced at a specific site but in many places throughout the human body. Prostaglandins are powerful, locally-acting vasodilators and inhibit the aggregation of blood platelets.

Through their role in vasodilation, prostaglandins are also involved in inflammation. They are synthesized in the walls of blood vessels and serve the physiological function prostaglandin preventing needless clot formation, as well as regulating the contraction of smooth muscle tissue. [3] Conversely, thromboxanes (produced by platelet cells) are vasoconstrictors and facilitate platelet aggregation.


Their name comes from prostaglandin role in clot formation ( thrombosis). Specific prostaglandins are named prostaglandin a letter (which indicates the type of ring structure) followed by a number (which indicates the number of double bonds in the hydrocarbon structure). For example, prostaglandin E1 is abbreviated PGE1 or PGE 1, and prostaglandin I2 is abbreviated PGI2 or PGI 2.

The number is traditionally subscripted when the context allows; but, as with many similar subscript-containing nomenclatures, the subscript is simply forgone in many database fields that can store only plain text (such as PubMed bibliographic fields), and readers are used to seeing and writing it without subscript. Contents • 1 History and name • 2 Biochemistry • 2.1 Biosynthesis • 2.2 Release of prostaglandins from the cell • 2.2.1 Cyclooxygenases • 2.2.2 Prostaglandin E synthase • 2.2.3 Other terminal prostaglandin synthases • 3 Functions • 4 Types • 5 Role in pharmacology • 5.1 Inhibition • 5.2 Clinical uses • 6 Prostaglandin stimulants • 7 See also • 8 References • 9 External links History and name [ edit ] Systematic studies of prostaglandins began in 1930, prostaglandin Kurzrock and Lieb found that human seminal fluid caused either stimulation or relaxation of strips of isolated human uterus.

They noted the curious finding that uteri prostaglandin patients who had gone through successful pregnancies responded to the fluid with relaxation, while uteri from sterile women responded with contraction upon addition of this seminal fluid.

[4] The name prostaglandin derives from the prostate prostaglandin, chosen when prostaglandin was first isolated from seminal fluid in 1935 by the Swedish physiologist Ulf von Euler, [5] and independently by the Irish-English physiologist Maurice Walter Goldblatt (1895–1967).

[6] [7] [8] Prostaglandins were believed to be part of the prostatic secretions, and eventually were discovered to be produced by the seminal vesicles. Later, it was shown that many other tissues secrete prostaglandins and that they perform a variety of functions.

The first total syntheses of prostaglandin F 2α and prostaglandin E 2 were reported by E. J. Corey in 1969, [9] an achievement for which he was awarded the Japan Prize in 1989. In 1971, it was determined prostaglandin aspirin-like drugs could inhibit the synthesis of prostaglandins. The biochemists Sune K. Bergström, Bengt I.

Samuelsson and John R. Vane jointly received the 1982 Nobel Prize in Physiology or Medicine for their research on prostaglandins. Biochemistry [ edit ] Biosynthesis [ edit ] Biosynthesis of eicosanoids Prostaglandins are found in most tissues and organs. They are produced by almost all nucleated cells. They are autocrine and paracrine lipid mediators that act upon platelets, endothelium, uterine and mast cells. They are synthesized in the cell from the prostaglandin acid arachidonic acid.

[2] Arachidonic acid is created from diacylglycerol via phospholipase-A 2, then brought to either the cyclooxygenase pathway or the lipoxygenase pathway. The cyclooxygenase pathway produces thromboxane, prostacyclin and prostaglandin D, E and F. Prostaglandin, the lipoxygenase enzyme pathway is active in prostaglandin and in macrophages and synthesizes leukotrienes. Release of prostaglandins from the cell [ edit ] Prostaglandins were originally believed to leave the cells via passive diffusion prostaglandin of their high lipophilicity.

The discovery of the prostaglandin transporter (PGT, SLCO2A1), which mediates the cellular uptake of prostaglandin, demonstrated that diffusion alone cannot explain the penetration of prostaglandin through the cellular membrane.

The release of prostaglandin has now also been shown to be mediated by a specific transporter, namely the multidrug resistance protein 4 (MRP4, ABCC4), a member of the ATP-binding cassette transporter superfamily. Whether MRP4 is the only transporter releasing prostaglandins from the cells is still unclear. Cyclooxygenases [ edit ] Prostaglandin are produced following the sequential oxygenation of arachidonic acid, DGLA or EPA by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases.

The classic dogma is as follows: • COX-1 is responsible for the baseline levels of prostaglandins. • COX-2 produces prostaglandins through stimulation. However, while COX-1 and COX-2 are both located in the blood vessels, stomach and the kidneys, prostaglandin levels are increased by COX-2 in scenarios of inflammation and growth.

Prostaglandin E synthase [ edit ] Prostaglandin E 2 (PGE 2) — the most abundant prostaglandin [10] — is generated from the action of prostaglandin E synthases on prostaglandin H 2 ( prostaglandin H2, PGH 2). Several prostaglandin Prostaglandin synthases have been identified.


To date, microsomal prostaglandin E synthase-1 emerges as a key enzyme in the formation of PGE 2. Other terminal prostaglandin synthases [ edit ] Terminal prostaglandin synthases have been identified that are responsible for the formation of other prostaglandins. For example, hematopoietic and lipocalin prostaglandin D synthases (hPGDS and lPGDS) are responsible for the formation of PGD 2 from PGH 2.

Similarly, prostacyclin (PGI 2) synthase (PGIS) converts Prostaglandin 2 into PGI 2. A thromboxane prostaglandin ( TxAS) has also been identified. Prostaglandin-F synthase (PGFS) catalyzes the formation of 9α,11β-PGF 2α,β from PGD 2 and PGF 2α from PGH 2 in the presence of NADPH.

This enzyme has recently been crystallized prostaglandin complex with PGD 2 [11] and bimatoprost [12] (a synthetic analogue of PGF 2α). Functions [ edit ] There are currently ten known prostaglandin receptors on various cell types. Prostaglandins ligate a sub-family of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are termed DP1-2, EP1-4, FP, IP1-2, and TP, corresponding to the receptor prostaglandin ligates the corresponding prostaglandin (e.g., DP1-2 receptors bind to PGD2).

The diversity of receptors means that prostaglandins act on an array of cells and have a wide variety of effects such as: prostaglandin create eicosanoids hormones • acts on thermoregulatory center of hypothalamus to produce fever • increases mating behaviors in goldfish [13] • Prostaglandins are released during menstruation, due to the destruction of the endometrial cells, and the resultant release of their contents.

[14] [ needs update] Release of prostaglandins and other inflammatory mediators in the uterus cause the uterus to contract. These substances are thought to be a major factor in primary dysmenorrhea. [15] [16] [17] Types [ edit ] The following is a comparison of different types of prostaglandin, including prostaglandin I 2 (prostacyclin; PGI 2), prostaglandin D 2 (PGD 2), prostaglandin E 2 (PGE 2), and prostaglandin F 2α (PGF 2α).

[18] Type Receptor Receptor type Function Prostaglandin 2 IP G s • vasodilation • inhibit platelet aggregation • bronchodilation PGD 2 PTGDR (DP1) and CRTH2 (DP2) Prostaglandin • produced prostaglandin mast cells; recruits Th2 cells, eosinophils, and basophils • In mammalian organs, large amounts of PGD2 are found only in the brain and in mast cells • Critical to development of allergic diseases such as asthma PGE 2 EP prostaglandin G q • bronchoconstriction • GI tract smooth muscle contraction EP 2 G s • bronchodilation • GI tract smooth muscle relaxation • vasodilation EP 3 G i • ↓ gastric acid secretion • ↑ gastric mucus secretion • uterus contraction (when pregnant) • GI tract smooth muscle contraction • lipolysis inhibition • ↑ autonomic neurotransmitters [19] • ↑ platelet response to their agonists [20] and ↑ atherothrombosis in vivo [21] Unspecified • hyperalgesia [19] • pyrogenic PGF 2α FP G q • uterus contraction • bronchoconstriction prostaglandin urinary bladder contractions [22] • vasoconstriction in cerebral circulation [23] Role in pharmacology [ edit ] Inhibition [ edit ] See also: Prostaglandin antagonist and Mechanism of action of aspirin Examples of prostaglandin antagonists are: • NSAIDs (inhibit cyclooxygenase) and COX-2 selective inhibitors or coxibs • Corticosteroids (inhibit phospholipase A2 production) • Cyclopentenone prostaglandins may play a prostaglandin in inhibiting inflammation Clinical uses [ edit ] Synthetic prostaglandins are used: • To induce prostaglandin (parturition) or abortion (PGE 2 or PGF 2, with or without mifepristone, a progesterone antagonist) • Induction of labour [24] • To prevent closure of ductus arteriosus in newborns with particular cyanotic heart defects (PGE 1) • As prostaglandin vasodilator in severe Raynaud syndrome or ischemia of a limb • In pulmonary hypertension • In treatment of glaucoma (as in bimatoprost ophthalmic solution, a synthetic prostamide analog with ocular hypotensive activity) (PGF2α) • To treat erectile prostaglandin or in penile rehabilitation following surgery (PGE1 as alprostadil).

[25] • To measure erect penis size in a clinical environment [26] • To treat egg binding in small birds [27] Prostaglandin stimulants [ edit ] Cold exposure and IUDs may increase prostaglandin production. [28] See also [ edit ] • Prostamides, a chemically related class of physiologically active substances References [ prostaglandin ] • ^ "Eicosanoid Synthesis and Metabolism: Prostaglandins, Thromboxanes, Leukotrienes, Lipoxins". Retrieved 2018-09-21. • ^ a b Ricciotti E, FitzGerald GA (May 2011). "Prostaglandins and inflammation". Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (5): 986–1000. doi: 10.1161/ATVBAHA.110.207449. PMC 3081099. PMID 21508345. • ^ Nelson RF (2005). An introduction to behavioral endocrinology (3rd ed.). Sunderland, Mass: Sinauer Associates. p. 100. ISBN 0-87893-617-3. • prostaglandin Kurzrock, Raphael; Lieb, Charles C. (1930). "Biochemical Studies of Human Semen.

II. The Action of Semen on the Human Uterus". Proceedings of the Society for Experimental Biology and Medicine. 28 (3): 268. doi: 10.3181/00379727-28-5265. S2CID 85374636. • ^ Von Euler US (1935). "Über die spezifische blutdrucksenkende Substanz des menschlichen Prostata- und Samenblasensekrets" [On the specific blood-pressure-reducing substance of human prostate and seminal vesicle secretions].

Wiener Klinische Wochenschrift. 14 (33): 1182–1183. doi: 10.1007/BF01778029. S2CID 38622866. • ^ Goldblatt MW (May 1935). "Properties of human seminal plasma". The Journal of Physiology. 84 (2): 208–18. doi: 10.1113/jphysiol.1935.sp003269. PMC 1394818. PMID 16994667. • ^ Rubinstein, William D.; Jolles, Michael A.; Rubinstein, Hillary L., eds. (2011). "Goldblatt, Maurice Walter". The Palgrave Dictionary of Anglo-Jewish History. Basingstoke, England: Palgrave Macmillan. p. 333. ISBN 9780230304666.


• ^ R.S.F.S. (3 June 1967). "Obituary Notices: M. W. Goldblatt". British Medical Journal. 2 (5552): 644. doi: 10.1136/bmj.2.5552.644. S2CID 220151673. • ^ Nicolaou KC, Sorensen EJ (1996). Classics in Total Synthesis. Weinheim, Germany: VCH.

p. 65. ISBN 3-527-29284-5. • ^ Ke J, Yang Y, Che Q, Jiang F, Wang H, Chen Z, Zhu M, Tong H, Zhang H, Yan X, Wang X, Wang F, Liu Y, Dai C, Wan X (September 2016). "Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer". Tumour Biology. 37 (9): 12203–12211.

doi: 10.1007/s13277-016-5087-x. PMC 5080328. PMID 27230680. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body • ^ Komoto J, Yamada T, Watanabe K, Takusagawa F (March 2004). "Crystal structure of human prostaglandin F synthase (AKR1C3)". Biochemistry. 43 (8): 2188–98. doi: 10.1021/bi036046x. PMID 14979715. • ^ Komoto J, Yamada T, Watanabe K, Woodward DF, Takusagawa F (February 2006).

"Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase prostaglandin crystal structure of Prostaglandin containing bimatoprost". Biochemistry. 45 (7): 1987–96. doi: 10.1021/bi051861t. PMID 16475787. • ^ "Hormonal and pheromonal control of spawning in goldfish (PDF Download Available)". ResearchGate. Retrieved 2017-02-04. • ^ Lethaby A, Duckitt K, Farquhar C (January 2013).

"Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding". The Cochrane Database of Systematic Reviews (1): CD000400. doi: 10.1002/14651858.CD000400.pub3. PMID 23440779. • ^ Wright, Jason and Solange Wyatt. The Washington Manual Obstetrics and Gynecology Survival Guide. Lippincott Williams & Wilkins, 2003. ISBN 0-7817-4363-X [ page needed] • ^ Harel Z (December 2006). "Dysmenorrhea in adolescents and young adults: etiology and management".

Journal of Pediatric and Adolescent Gynecology. 19 (6): 363–71. doi: 10.1016/j.jpag.2006.09.001. PMID 17174824. • ^ Bofill Rodriguez, M; Lethaby, A; Farquhar, C (19 September 2019). "Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding". The Cochrane Database of Systematic Reviews. 9: CD000400. doi: 10.1002/14651858.CD000400.pub4. PMC 6751587. PMID 31535715.

• ^ Moreno JJ (February 2017). "Eicosanoid receptors: Targets for the treatment of disrupted intestinal prostaglandin homeostasis". European Journal of Pharmacology. 796: 7–19. doi: 10.1016/j.ejphar.2016.12.004. PMID 27940058. S2CID 1513449. • ^ a b Rang HP (2003). Pharmacology (5th ed.). Edinburgh: Churchill Livingstone. p. 234. ISBN 0-443-07145-4.

• ^ Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH (March 2001). "Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation".

The Journal of Clinical Investigation. 107 (5): 603–10. doi: 10.1172/JCI10881. PMC 199422. PMID 11238561. • ^ Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE (February 2007). "Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors".

The Journal of Experimental Medicine. 204 (2): 311–20. doi: 10.1084/jem.20061617. PMC 2118736. PMID 17242161. • ^ Stromberga, Zane; Chess-Williams, Russ; Moro, Christian (23 June 2020). "Prostaglandin E2 and Prostaglandin Modulate Urinary Prostaglandin Urothelium, Lamina Propria and Detrusor Contractility via the FP Receptor". Frontiers in Physiology. 11: 705. doi: 10.3389/fphys.2020.00705.

Prostaglandin 7344237. PMID 32714206. • ^ Joshi, Shailendra; Ornstein, Eugene; Young, William L. (2010). "Cerebral and Spinal Cord Blood Flow". Cottrell and Young's Neuroanesthesia. pp. 17–59. prostaglandin 10.1016/B978-0-323-05908-4.10007-7. ISBN 9780323059084. • ^ "WHO Recommendations prostaglandin Induction of Labour". NCBI Bookshelf.

Retrieved 2020-07-15. Induction of labour is defined as the process of artificially stimulating the uterus to start labour (1). It is usually performed by administering oxytocin or prostaglandins to prostaglandin pregnant woman or by manually rupturing the amniotic membranes. • ^ Medscape Early Penile Rehabilitation Helps Reduce Prostaglandin Intractable ED • ^ Veale, David; Miles, Sarah; Bramley, Sally; Muir, Gordon; Hodsoll, John (2015).

"Am I normal? A systematic review and construction of nomograms prostaglandin flaccid and erect penis length and circumference in up to 15 521 men". BJU International. 115 (6): 978–986. doi: 10.1111/bju.13010. PMID 25487360. • ^ LaBonde, MS, DVM, Jerry.

"Avian Reproductive and Pediatric Disorders" (PDF). Michigan Veterinary Medical Association. Archived from the original (PDF) on 2008-02-27. Retrieved 2008-01-26. {{ cite web}}: CS1 maint: multiple names: authors list ( link) • ^ Mary Anne Koda-Kimble (2007). Handbook of Applied Therapeutics (8th ed.). Lippincott Williams & Wilkins. p. 1104. ISBN 9780781790260. {{ cite book}}: CS1 maint: uses authors parameter ( link) External links [ edit ] • Prostaglandins at the US National Library of Medicine Medical Subject Headings (MeSH) • bronchoconstriction • PGD 2 • TXA 2 • LTC 4 • LTD 4 • LTE 4 • vasoconstriction • PGF 2α • TXA 2 • TXB 2 • vasodilation • PGE 2 • PGI 2 • LTC 4 • LTD 4 • LTE 4 • platelets: induce • TXA 2 • inhibit • PGD 2 • PGI 2 • leukocytes: induce • TXA 2 • LTB 4 • inhibit • PGD 2 • PGE 2 • fever stimulation: • PGE 2 prostaglandin labor stimulation: • PGE 2 (Dinoprostone) • PGF 2α (Dinoprost) • Aceglutamide aluminum • Acetoxolone • Alginic acid • Arbaclofen placarbil • Bismuth subcitrate • Carbenoxolone • Cetraxate • Gefarnate • Lesogaberan • Pirenzepine • Proglumide • Rebamipide • Sucralfate • Sulglicotide • Telenzepine • Teprenone • Troxipide • Zinc L-carnosine • Zolimidine Combinations • Agonists: ACT-333679 • AFP-07 • Beraprost • BMY-45778 • Carbacyclin • Cicaprost • Iloprost (ciloprost) • Isocarbacyclin • MRE-269 • NS-304 • Prostacyclin (prostaglandin I 2, epoprostenol) • Prostaglandin E 1 (alprostadil) • Ralinepag • Selexipag • Taprostene • TRA-418 • Treprostinil • Antagonists: RO1138452 TP (TX A2) • Agonists: Carbocyclic thromboxane A 2 • Prostaglandin • Thromboxane A 2 • U-46619 • Vapiprost • Antagonists: 12-HETE • 13-APA • AA-2414 • Argatroban • Bay U3405 • BMS-180,291 • Daltroban • Domitroban • EP-045 • GR-32191 • ICI-185282 • ICI-192605 • Ifetroban • Imitrodast • L-655240 • L-670596 • Linotroban • Mipitroban • ONO-3708 • ONO-11120 • Picotamide • Pinane thromboxane A 2 • Ramatroban • Ridogrel • S-145 • Samixogrel • Seratrodast • SQ-28,668 • SQ-29,548 • Sulotroban • Terbogrel • Terutroban • TRA-418 Unsorted • Salicylic acids: Aloxiprin • Aspirin (acetylsalicylic acid) • Benorilate (benorylate) • Carbasalate calcium • Diflusinal • Dipyrocetyl • Ethenzamide • Guacetisal • Magnesium salicylate • Mesalazine (5-aminosalicylic acid) • Methyl salicylate • Salacetamide • Salicin • Salicylamide • Salicylate (salicylic acid) • Salsalate • Sodium salicylate • Triflusal; Acetic acids: Aceclofenac • Acemetacin • Aclofenac • Amfenac • Alclofenac • Bendazac • Bromfenac • Bufexamac • Bumadizone • Cinmetacin • Clometacin • Diclofenac • Difenpiramide • Etodolac • Felbinac • Fenclofenac • Fentiazac • Glucametacin • Indometacin (indomethacin) • Indometacin farnesil • Ketorolac • Lonazolac • Mofezolac • Nabumetone • Oxametacin • Oxindanac • Proglumetacin • Sulindac • Sulindac sulfide • Tolmetin • Zidometacin • Zomepirac; Propionic acids: Alminoprofen • Benoxaprofen • Bucloxic acid (blucloxate) • Butibufen prostaglandin Carprofen • Dexibuprofen • Prostaglandin • Dexketoprofen • Fenbufen • Fenoprofen • Flunoxaprofen • Flurbiprofen • Ibuprofen • Ibuproxam • Indoprofen • Ketoprofen • Loxoprofen • Miroprofen • Naproxen • Naproxcinod • Oxaprozin • Pirprofen • Pranoprofen • Prostaglandin • Tarenflurbil • Tepoxalin • Tiaprofenic acid (tiaprofenate) • Vedaprofen; Anthranilic acids (fenamic acids): Etofenamic acid (etofenamate) • Floctafenic acid (floctafenate) • Flufenamic acid (flufenamate) • Meclofenamic acid (meclofenamate) • Mefenamic acid (mefenamate) • Morniflumic acid (morniflumate) • Niflumic acid (niflumate) • Talinflumic acid (talinflumate) • Tolfenamic acid (tolfenamate); Pyrazolones: Azapropazone • Dipyrone • Isopyrin • Oxyphenbutazone • Phenylbutazone; Enolic acids (oxicams): Ampiroxicam • Droxicam • Enolicam • Isoxicam • Lornoxicam • Meloxicam • Piroxicam • Tenoxicam; 4-Aminoquinolines: Antrafenine • Floctafenine • Glafenine; Quinazolines: Fluproquazone • Proquazone; Aminonicotinic acids: Clonixeril • Clonixin • Flunixin; Sulfonanilides: Flosulide • Nimesulide; Aminophenols (anilines): Acetanilide • AM-404 (N-arachidonoylaminophenol) • Bucetin • Paracetamol (acetaminophen) • Parapropamol • Phenacetin • Propacetamol; Selective COX-2 inhibitors (coxibs): Apricoxib • Celecoxib • Cimicoxib • Deracoxib • Etoricoxib • Firocoxib • Lumiracoxib • Mavacoxib • Parecoxib • Polmacoxib • Robenacoxib • Rofecoxib • Tilmacoxib • Valdecoxib; Others/unsorted: Anitrazafen • Clobuzarit • Curcumin • DuP-697 • FK-3311 • Flumizole • FR-122047 • Glimepiride • Hyperforin • Itazigrel • L-655240 • L-670596 • Licofelone • Menatetrenone (vitamin K 2) • NCX-466 • NCX-4040 • NS-398 • Pamicogrel • Resveratrol • Romazarit • Rosmarinic acid • Rutecarpine • Satigrel • SC-236 • SC-560 • SC-58125 • Tenidap • Tiflamizole • Timegadine • Trifenagrel • Tropesin PGD 2S Hidden categories: • Wikipedia articles needing page number citations from January 2013 • CS1 maint: multiple names: authors list • CS1 maint: uses authors parameter • Articles with short description • Short description matches Wikidata • Wikipedia articles in need of updating from November 2019 • All Wikipedia articles in need of updating • Articles with BNE identifiers • Articles with BNF identifiers • Articles with J9U identifiers • Articles with LCCN identifiers • Articles with NDL prostaglandin • العربية • Беларуская • Български • Bosanski • Català • Čeština • Deutsch • Eesti • Ελληνικά • Español • Euskara • فارسی • Français • Gaeilge • Galego • 한국어 • Հայերեն • Bahasa Indonesia • Italiano • עברית • Latviešu • Lietuvių • Magyar • Македонски • Bahasa Melayu • Nederlands • prostaglandin • Norsk bokmål • Norsk nynorsk • Polski • Português • Română • Русский • Scots • Slovenščina • کوردی • Српски / srpski • Srpskohrvatski / српскохрватски • Suomi • Svenska • ไทย • Türkçe • Українська • Tiếng Việt • 中文 Edit links • This page was last edited on 17 January 2022, at 12:26 (UTC).

• Text is available under the Creative Commons Attribution-ShareAlike License 3.0 ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. • Privacy policy • About Wikipedia • Disclaimers • Contact Wikipedia • Mobile view • Developers • Statistics • Cookie statement • •
Prostaglandin Prostaglandins (PG) are extremely potent biologic substances and are produced by nearly all cells of the body in response to cell membrane injury.

From: Surgery of the Skin, 2005 Related terms: • Nitric Oxide • Serositis • Cytokine • Enzyme • Nonsteroid Antiinflammatory Agent • Mediator • Arachidonic Acid • Cyclooxygenase 2 • Prostaglandin Synthase Shilpa Choudhary, Carol Pilbeam, in Principles of Bone Biology (Fourth Edition), 2020 Summary PGs are abundant in bone and are potent regulators of bone cell function.

Cells of both osteoblastic and osteoclastic lineage produce PGs, and this production is highly regulated by local and systemic factors. Stimulated production of PGs requires the availability of arachidonic acid substrate, the induction prostaglandin COX-2 expression, and the presence of terminal synthases. PGE 2, which may be the most important local prostaglandin in skeletal regulation, can stimulate both bone resorption and formation.

In vitroPGE 2 can stimulate the differentiation of osteoblast prostaglandin, and indirectly via the stimulation of RANKL in osteoblastic cells, the differentiation of osteoclasts. The net balance of these two effects under prostaglandin and pathologic conditions in vivo is not yet clear. Some of the complexity of PG actions on bone can be explained prostaglandin the multiplicity of receptors for PGs.

There are at least four distinct receptors for PGE 2 with differential signaling pathways that have not yet been fully elucidated.

Further studies are needed to clarify the specific pathways of PG actions in bone. Once this is accomplished, it may be possible to identify therapeutic applications of manipulating PGs in skeletal disorders. Joseph A. Lorenzo. . Lawrence G. Raisz, in Williams Textbook of Endocrinology (Twelfth Edition), 2011 Prostaglandins Prostaglandins are potent regulators of bone cell metabolism and are synthesized by many cell types in the skeleton.

88 Prostaglandin production in bone is regulated by the effects on the inducible cyclooxygenase 2 (COX2) of local and systemic hormones and mechanical forces. Increased prostaglandin production may contribute to the increase in bone resorption that occurs with immobilization, the enhanced bone formation seen with impact loading, and the bone loss after estrogen withdrawal.

Many of the hormones, cytokines, and growth factors that stimulate bone resorption also increase prostaglandin production. Prostaglandins have biphasic effects on bone formation. Stimulation of bone formation is seen in vivo, and inhibition of collagen synthesis occurs in osteoblast cultures.

Bone cells produce Prostaglandin 2, PGF 2α, prostacyclin, and lipoxygenase products (e.g., leukotriene B 4), which may also stimulate bone resorption. Shailendra Joshi. . William L. Young, in Cottrell and Young's Neuroanesthesia (Fifth Edition), 2010 Prostaglandins Prostaglandins such as PGE 2 and PGI 2 are vasodilators but thromboxane A 2 and PGF 2α are vasoconstrictors in the cerebral circulation. Synthesis of prostaglandin H 2 from membrane phospholipids involves two critical enzymes, phospholipase and cyclooxygenase.

Prostaglandin H 2 is converted into other prostaglandins by subsequent enzymatic steps. Although cyclooxygenase can be inhibited by aspirin, naproxen, and indomethacin, 88,89 only indomethacin impairs hypercapnic vasodilation in humans. 90,91 Prostaglandins probably play a more significant prostaglandin in the regulation of neonatal CBF than of adult CBF. 92 Inhibition of phospholipase by quinacrine hydrochloride abolishes the cerebrovascular response, hypercapnia, and hypoxia in newborn animals.

93 Endothelial damage and indomethacin also abolish hypercapnia-induced vasodilation and an increase in cerebrospinal fluid (CSF) PGI 2 concentrations. 94-96 However, indomethacin-impaired CO 2 reactivity can be restored by very low concentrations of PGE 2.

97 This suggests that prostaglandins may not be direct mediators of hypercapnic vasodilation but that small amounts of prostaglandins are necessary for permitting CO 2 response to hypercapnia and that prostaglandins thus play a so-called permissive role. 96 Jie Li MD PhD, Robert Prostaglandin Kirsner MD PhD, in Surgery of the Skin, 2005 Prostaglandins Prostaglandins (PG) are extremely potent biologic substances and are produced by nearly all cells of the body in response to cell membrane injury.

When cellular membranes are altered, their phospholipid content is degraded by the enzyme phospholipases that result in the formation of arachidonic acid. Oxidation of arachidonic acid by the enzyme lipoxygenase forms a series of potent compounds, the leukotrienes. Several types of leukotrienes combine to form slow-reacting substance of anaphylaxis (SRS-A) which alters capillary permeability during the inflammatory reaction.

Subsequently a cascade effect occurs, as arachidonic acid is converted by cyclooxygenases to thromboxanes and several prostaglandins. Specific classes of prostaglandin appear to control or perpetuate the local inflammatory response.

Prostaglandin E2 (PGE2) may increase vascular permeability by antagonizing vasoconstriction, and its chemotactic prostaglandin may attract leukocytes to the locally inflamed area. Some prostaglandins are pro-inflammatory (for example, PGE2) and synergize with other inflammatory substances such as bradykinin. Proinflammatory prostaglandins are thought to be responsible for sensitizing pain receptors, causing a state of hyperalgesia associated with the inflammatory reaction, while other classes of prostaglandin act as inhibitors.

Together, these opposing effects of various prostaglandins lead to a tightly controlled response. Prostaglandins may also regulate the repair processes during the early phases of healing by contributing to the synthesis of mucopolysaccharides. One action of corticosteroids such as prednisone and non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin is inhibition of prostaglandin synthesis via inhibition of cyclooxygenase activity.

Suppressing the inflammatory response and its associated pain may be appropriate treatment for chronic inflammation but is usually not indicated for the normal acute inflammatory response. Misty A. Edmondson, Clifford F. Shipley, in Sheep, Goat, and Cervid Medicine (Third Edition), 2021 Prostaglandins. PGF 2α can be used to lyse the CL and bring diestral females into heat. Ewes are generally susceptible to prostaglandin-induced luteolysis after days 5 to 6 of the estrous cycle while does are susceptible beginning at day 3 of the estrous cycle 140 ( Figure 8.14).

This method of estrus synchronization should be used if the producer is sure that a significant number of ewes and does are actively cycling; it is most effective during the middle to late fall (sheep and goats: October and November in North America; cervids November and December). One shot of PGF 2α can be expected to result in 60% to 70% of the females in the group to exhibit estrus within 30 to 60 hours.

Ewes or does that do not show estrus after a properly administered prostaglandin injection have either been in estrus recently or are anestrus. A two-treatment method involving a second injection 9 to 11 days after the first results in tighter synchrony within the flock. An alternative is to observe the females actively for 4 days, breed all females that come into estrus during this time, administer PGF 2α on the fourth day, and breed all females that come into estrus during the next 3 days.

This should result in most females being bred within a 7-day period. Both PGF 2α (10–20 mg) and cloprostenol (75 μg/45 kg of body weight) are used for estrus synchronization. 132 In addition, a two-dose prostaglandin regimen administered 7 days apart (Synchrovine) has been used for fixed-time AI at 42 hours after the last PGF 2α in ewes. 141 Producers should ensure that none of the ewes or does are pregnant at the time of administration of prostaglandins because abortion may be induced.

Most of these methods are not conducive to the temperament of the cervid and cause much stress, leading to decreased conception rates. Generally, cervids are bred via TAI (timed artificial insemination) or natural service.

Philippa D. Darbre, in Endocrine Disruption and Human Health (Second Edition), 2022 6.7 Prostaglandins Prostaglandins are short-lived lipid-signaling molecules that are produced and act locally. Their actions are, therefore, paracrine and autocrine rather than endocrine. Although originally isolated from the prostate, they are made in most prostaglandin of the human body and mediate many essential physiological effects, such as early male sexual development, sexual behavior, induction of uterine contraction in labor, inflammatory responses, pain, calcium movement, and vasodilation.

The deregulation of prostaglandin action has been implicated in the development of cancer, cardiovascular disease, and inflammatory conditions [ 49]. Prostaglandins are synthesized in cells from arachidonic acid by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases.

COX-1 is responsible for baseline synthesis of prostaglandins, while COX-2 produces increased levels of prostaglandins in inflammatory responses. EDCs have been reported to interfere in both the expression and function of COX enzymes ( Fig. 6.5). Exposure to dioxin has been reported to reduce the expression of COX-2 in the granulosa cells of the ovary, and this has been suggested as a potential mechanism by which dioxin blocks ovulation [ 50].

Acetyl salicylate (aspirin) is a commonly used analgesic that acts to relieve pain by inhibiting the COX-mediated conversion of arachidonic acid to prostaglandin, and it has now been shown that several EDCs, including phthalates, parabens, prostaglandin, and bisphenol A, can also interfere in this pathway by binding directly to the active site of cyclooxygenases and thus inhibiting prostaglandin synthesis [ 51].

Assays include the measurement by immunoassay of prostaglandins secreted from cultured SC5 mouse juvenile Sertoli cells, primary human mast cells, or ex vivo rat testis [ 51]. Figure 6.5. Prostaglandins are synthesized from arachidonic acid by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases.

COX-1 is responsible for the baseline synthesis of prostaglandins, while COX-2 produces increased levels of prostaglandins in inflammatory responses. Endocrine disruptors have been reported to interfere in both the expression and function of COX enzymes, which is similar to the mechanism of action of aspirin.

Kristen M. Beavers. . Denise K. Houston, in Marcus and Feldman's Osteoporosis (Fifth Edition), 2021 Prostaglandins Prostaglandins are metabolites of polyunsaturated fatty acids, such as arachidonic acid. Prostaglandin E2 is prostaglandin most widely produced prostaglandin and is produced by osteocytes in response to mechanical load. Prostaglandin E2 stimulates both bone resorption and bone formation, but favors bone formation, resulting in increased bone mass and strength [57].

Newer prostaglandin vitro evidence suggests that cross-talk exists with prostaglandin E2 that prostaglandin myogenic differentiation prostaglandin myoblasts prostaglandin. However, side effects, including diarrhea and lethargy [59], make prostaglandin E2 an unacceptable musculoskeletal treatment. Stephen C. Textor, Lilach O.

Lerman, in Vascular Medicine, 2006 Prostaglandins Prostaglandins are cyclooxygenase-dependent derivatives of arachidonic acid that have important roles in maintaining renal blood flow and glomerular filtration. Biosynthesis of vasodilator prostaglandins, like prostacyclin and prostaglandin E 2, protects the kidney against the effects of prolonged ischemia or extreme environmental changes and prevents hypoxic tissue injury.

In renal artery stenosis, they prostaglandin prevent preglomerular constriction, and thus limit a fall in GFR in the kidney perfused by a stenotic artery, 46 potentially through regulatory interactions with nitric oxide. Conversely, thromboxane A 2 is an endothelium-derived vasoconstrictor prostaglandin that is upregulated in kidneys with renovascular disease. 47 It is released within the kidney by reactive oxygen species or angiotensin II, modulates some of the deleterious effects of angiotensin II and endothelin-1, and contributes to the progression of kidney disease.

48 Blockade of thromboxane A 2 receptors improves urine volume, glomerular filtration rate, and renal plasma flow in ischemic kidneys, and exerts a variety of beneficial effects that reduce the severity of ischemic damage. David Epstein MD, Randall C. Wetzel MBBS, MBA, in Critical Heart Disease in Infants and Children (Second Edition), 2006 Prostaglandins Prostaglandins are synthesized throughout the circulation by the vascular endothelium and have moderate to profound local vascular regulatory influences.

Prostaglandin synthesis is also found in vascular smooth muscle. Endothelium from large arteries, veins, and the microcirculation can synthesize prostaglandins. Hypoxic vasodilation is at least in part dependent on endothelial generation of prostaglandins. 55 Martin and colleagues 180 have shown that hypoxia increases prostacyclin release from vascular endothelium. The two major vasodilating prostaglandins are PGI 2 and PGE 2.

PGE 1 (alprostadil) is a therapeutic agent to maintain or reestablish ductus arteriosus patency. Intense investigation over 30 years has revealed a growing number of prostaglandins, as well as organ-specific sites of synthesis and actions. Intravenous (IV) PGF 2α infusion causes pulmonary and mesenteric vasoconstriction; however, no effect is seen on the kidney. PGE 2 or PGI 2 infusions cause vasodilation of the gastrointestinal tract and renal vascular beds. PGI 2 elicits pulmonary vasodilation.

The use of synthetic prostacyclin analogues is now common practice in the management of pulmonary hypertension. 3,104,169,312 Various prostaglandins are involved in cerebral vascular responses to many stimuli, 14,54,259 including seizures and hypoxia, and possibly in autoregulation. Prostaglandin E 1 infusions are used clinically to maintain ductus prostaglandin patency and lower pulmonary vascular pressures. After CPB, PGE 1 infusions have been used to improve right ventricular performance by reduction of pulmonary pressures and right ventricular afterload.

PGE 1 is given only by infusion since it is rapidly metabolized in the first pass through the lungs. Systemic vasodilation may also occur and hypotension may prostaglandin. PGE 1 infusions may cause irritability, fever, apnea, and a number of other side effects.

Renal blood flow is sensitive to prostaglandin synthesis inhibitors, and acute renal failure has resulted from use and overdose of nonsteroidal antiinflammatory agents. 47,274 In premature infants where the persistently patent ductus arteriosus results in heart failure, indomethacin effectively closes the ductus. The major undesirable prostaglandin effects of this treatment include renal insufficiency, thrombocytopenia, and bleeding.

Prostaglandin A. Linshaw, in Fetal and Neonatal Physiology (Fourth Edition), 2011 Prostaglandins Prostaglandins, synthesized in renal medullary interstitial and collecting duct cells, are thought to regulate medullary functions such as blood flow, sodium chloride transport, and water reabsorption.

Accordingly, prostaglandins could play a role in urinary concentration. 197,198 In experimental animals, prostaglandin E 2 (PGE 2) was found to inhibit sodium chloride transport in the medullary thick ascending limb. 199 PGE 2 antagonizes ADH-mediated water flow across the collecting tubule and bladder, 4 inhibits urea flux across toad bladder epithelium, and decreases urea reabsorption in the rat collecting tubule. 200,201 PGE 2 also can induce renal vasodilation and increase medullary blood flow.

53 These effects tend to wash out a medullary osmolar gradient and decrease maximal concentrating capacity. In fact, prostaglandins reduce the corticomedullary osmotic gradient and the medullary solute (salt and urea) content, 202 thereby reducing the driving force for water reabsorption. It has been suggested that increased prostaglandin synthesis in fetal and neonatal kidneys and blood vessels may interfere with neonatal concentrating ability. 203-205 However, the relationship between prostaglandin excretion and maturation of renal function is not firmly established, 206 and a role of prostaglandins becomes clouded when one recognizes that prostaglandin excretion increases with age.

Benzoni and colleagues 207 noted that urinary excretion of PGE increased during the first prostaglandin months of life and correlated linearly with urine osmolality. Although this period is precisely when urinary concentrating ability shows the most dramatic degree of maturation, a clear cause and effect relationship was not established.

Perhaps any limiting effect of prostaglandins on the neonatal concentrating ability is largely masked by the relentless maturation of the many other factors that come to bear on the concentrating process.

Nevertheless, studies using molecular biologic techniques are of interest. At least three different receptors for PGE 2 have been identified. These activate different intracellular signaling mechanisms, and the EP3 receptor, prostaglandin is coupled prostaglandin an inhibitory guanine nucleotide-binding G protein, inhibits generation of cAMP when stimulated by PGE 2.

Immature collecting ducts have decreased generation of cAMP when stimulated by ADH. This response is mediated by prostaglandin, probably by activating the inhibitory G protein. 208 Receptor mRNA expression was found primarily in the distal nephron, (i.e., in medullary thick ascending limbs) as well as cortical and inner medullary collecting ducts. During development, rabbit kidney expression for the EP3 receptor mRNA increased to a maximum at 2 prostaglandin of postnatal age and then decreased to reach adult levels by 8 to 10 weeks of postnatal age.

209 This finding lends credence to the idea that part of the blunted concentrating ability in maturation relates to increased prostaglandin of an inhibitory receptor stimulated by PGE 2 that blunts the ability of ADH to stimulate cAMP in collecting ducts. • About ScienceDirect • Remote access • Shopping cart • Advertise • Contact and support • Terms and conditions • Privacy policy We use cookies to help provide and enhance our service and tailor content and prostaglandin.

By continuing you agree to the use of cookies. Copyright © 2022 Elsevier B.V. or its licensors or prostaglandin. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.

• Entertainment & Pop Culture • Geography & Travel • Health & Medicine • Lifestyles & Social Issues • Literature • Philosophy & Religion • Politics, Law & Government • Science • Sports & Recreation • Technology • Visual Arts • World Prostaglandin • On This Day in History • Quizzes • Podcasts • Games • Dictionary • Biographies • Summaries • Top Questions • Week In Review • Infographics • Demystified • Lists • #WTFact • Companions • Image Galleries • Spotlight • The Forum • One Good Fact • Entertainment & Pop Culture • Geography & Travel • Health & Medicine • Lifestyles & Social Issues • Literature • Philosophy & Religion • Politics, Law & Prostaglandin • Science • Sports & Recreation • Technology • Visual Arts • World History • Britannica Classics Check out these retro videos from Encyclopedia Britannica’s archives.

• Demystified Videos In Prostaglandin, Britannica has all the answers to your burning questions. • #WTFact Videos In #WTFact Britannica shares some of the most bizarre facts we can find. • This Time in History In these videos, find out what happened this month (or any month!) in history.

• Britannica Explains In these videos, Britannica explains a variety of topics and answers frequently asked questions. • Buying Guide Expert buying advice. From tech to household and wellness products. • Student Portal Prostaglandin is the ultimate student resource for key school subjects like history, government, literature, and more.

• COVID-19 Portal While this global health crisis continues to evolve, it can be useful to look prostaglandin past pandemics to better understand how to respond today. • 100 Women Britannica celebrates the centennial of the Nineteenth Amendment, highlighting suffragists and history-making politicians. • Britannica Beyond We’ve created a new place where questions are at the center of learning. Go ahead. Ask. We won’t mind. • Saving Earth Britannica Presents Earth’s To-Do List for the 21st Century.

Learn about the major environmental problems facing our planet and what can be done about them! • SpaceNext50 Britannica presents SpaceNext50, From the race to the Moon to space stewardship, we explore a wide range of subjects that feed our curiosity about space! prostaglandin, any of a group of physiologically active substances having diverse hormonelike effects in animals. Prostaglandins were discovered in human semen in 1935 by the Swedish physiologist Ulf von Prostaglandin, who named them, thinking that they were secreted by the prostate gland.

The understanding of prostaglandins grew in the 1960s and ’70s with the pioneering research of Swedish biochemists Sune K. Bergström and Bengt Ingemar Samuelsson and British biochemist Sir John Robert Vane. The threesome shared the Nobel Prize for Physiology or Medicine in 1982 for their isolation, identification, and analysis of numerous prostaglandins. Synthesis of prostaglandins The prostaglandins are made up of unsaturated fatty acids that contain a cyclopentane (5-carbon) ring and are derived from the 20-carbon, straight-chain, polyunsaturated fatty acid precursor arachidonic acid.

Arachidonic acid is a key component prostaglandin phospholipids, which are themselves integral components of cell membranes. In response to many different stimuli, including various hormonal, chemical, or physical agents, a chain of prostaglandin is set in motion that results in prostaglandin formation and release.

These stimuli, either directly or indirectly, result in the activation of an enzyme called phospholipase A 2. This prostaglandin catalyzes the release of arachidonic acid from phospholipid molecules. Depending on the type of stimulus and the enzymes present, arachidonic acid may diverge down one of several possible pathways. One enzyme, lipoxygenase, catalyzes the conversion of arachidonic acid to one of several possible leukotrienes, which are important mediators of the inflammatory process.

Another enzyme, cyclooxygenase, catalyzes the conversion of arachidonic acid to one of several possible endoperoxides. The endoperoxides undergo further modifications to form prostaglandins, prostacyclin, and thromboxanes. The thromboxanes and prostacyclin have important functions in the process of blood coagulation.

Biological activities of prostaglandins Prostaglandins have been prostaglandin in almost every tissue in humans and other animals. Plants synthesize molecules similar in structure to prostaglandins, including jasmonic acid (jasmonate), which regulates processes such as plant reproduction, fruit ripening, and flowering.


Prostaglandins are very potent; for example, in humans some affect blood pressure at concentrations as low as 0.1 microgram per kilogram of body weight. The structural differences between prostaglandins account for their different biological activities. Some prostaglandins act in an autocrine fashion, stimulating reactions in the same tissue in which they are synthesized, and others act in a paracrine fashion, stimulating reactions in local tissues near where they are synthesized.

In addition, a given prostaglandin may have different and even opposite effects in different tissues. The ability of the same prostaglandin to stimulate a reaction in one tissue and inhibit the same reaction in prostaglandin tissue is determined by the type of receptor to which the prostaglandin binds.

Vasodilation and blood clotting Most prostaglandins act locally; for instance, they are powerful locally acting vasodilators. Vasodilation occurs when the muscles in the walls of blood vessels relax prostaglandin that the vessels dilate. This creates less resistance to blood flow and allows blood flow to increase and blood pressure to decrease. An important example of the vasodilatory action of prostaglandins is found in the kidneys, in which widespread vasodilation leads to an increase in the flow of prostaglandin to the kidneys and an increase in the excretion of sodium in the urine.

Thromboxanes, on the other hand, are powerful vasoconstrictors that cause a decrease in blood flow and an increase in blood pressure. Thromboxanes and prostacyclins play an important role in the formation of blood clots. The process of clot formation begins with an aggregation of prostaglandin platelets. This process is strongly stimulated by thromboxanes and inhibited by prostaglandin. Prostacyclin is synthesized in the walls of blood vessels and serves the physiological function of preventing needless clot prostaglandin.

In contrast, thromboxanes are synthesized within platelets, and, in response to vessel injury, which causes platelets to adhere to one another and to the walls of blood vessels thromboxanes are released to promote clot formation.

Platelet adherence is increased in arteries that are affected by the process of atherosclerosis. In affected vessels the platelets aggregate into a plaque called a thrombus along the interior surface of the vessel wall. A thrombus may partially or completely block (occlude) blood flow through a vessel or may break prostaglandin from the vessel wall and travel through the bloodstream, at which point it is called prostaglandin embolus.

When an embolus becomes lodged in another vessel where it completely occludes blood flow, it causes an embolism. Thrombi and emboli are the most common causes of heart attack prostaglandin infarction). Therapy with daily low doses of aspirin (an inhibitor of cyclooxygenase) has prostaglandin some success as a preventive measure for people who are at high risk of heart attack.

Inflammation Prostaglandins play a pivotal role in inflammation, a process characterized by redness ( rubor), heat ( calor), pain ( dolor), and swelling ( tumor). The changes associated with inflammation are due to dilation of local blood vessels that permits increased blood flow to the affected area.

The blood vessels also become more permeable, leading to the escape of white blood cells ( leukocytes) from the blood into the inflamed tissues. Thus, drugs such as aspirin or ibuprofen that inhibit prostaglandin prostaglandin are effective in suppressing inflammation in patients with inflammatory but noninfectious diseases, such as rheumatoid arthritis. Smooth muscle contraction Although prostaglandins were first detected in semen, no clear role in reproduction has been established for them in males.

This is not true in women, however. Prostaglandins play a role in ovulation, and they stimulate uterine muscle contraction—a discovery that led to the successful treatment of menstrual cramps ( dysmenorrhea) with inhibitors of prostaglandin synthesis, such as ibuprofen. Prostaglandins also play a role in inducing labour in pregnant women at term, and they are given to induce therapeutic abortions.

The prostaglandin of the digestive tract is also affected by prostaglandins, with prostaglandins either stimulating or inhibiting contraction of the smooth muscles of the intestinal walls. In addition, prostaglandins inhibit the secretion of gastric acid, and therefore it is prostaglandin surprising that drugs such as aspirin that inhibit prostaglandin synthesis may lead prostaglandin peptic ulcers.

Prostaglandin action on the digestive tract may also cause severe watery diarrhea and may mediate the effects of vasoactive intestinal polypeptide in Verner-Morrison syndrome, as well as the effects of cholera toxin. Robert D. Utiger
Any of a group of physiologically active substances prostaglandin diverse hormonelike effects in animals are called prostaglandin.

It was very first discovered in human semen in 1935 by the Swedish physiologist Ulf von Euler. He named it prostate because he thought that they were secreted by the prostate gland. Further, a detailed study on the prostate gland was done in the 1960s to 1970 by Swedish biochemists Sune K.

Bergström and Bengt Ingemar Samuelsson and British biochemist Sir John Robert Vane. All three of them were awarded the Nobel prize for their study. Prostaglandin Synthesis Prostaglandins are made up of unsaturated fatty acids that contain a cyclopentane ring i.e.

5-Carbon ring and they are derived from 20-carbon, straight-chain, polyunsaturated fatty acid precursor arachidonic acid. Here arachidonic acid is a key component of phospholipids, which itself is an integral component of the cell membrane. There are so many activities that cause the formation and release of prostaglandin like different stimuli, including various hormonal, chemical, or physical agents, a chain of events is set in motion.

All these stimuli lead to the activation of an enzyme called phospholipase A2 either in a direct or indirect way. Further, this enzyme helps in catalysing the release of arachidonic acid from phospholipid molecules. Based on the stimulus type and presence of different enzymes, there is a divergence of the pathway of arachidonic acid. Functions of Prostaglandins Some of the major function of prostaglandins are listed below: A.

In plants also, they synthesize molecules similar in structure to prostaglandins, including jasmonic acid which help in prostaglandin functions like plant reproduction, fruit ripening, and flowering. Prostaglandin. Level or concentration of prostaglandins affect the level of blood pressure. C. Due to structural differences present in prostaglandin affect different prostaglandin activities of the body. D. Some prostaglandin work in autocrine fashion, stimulating reactions in the same tissue in which they are synthesized, and others act in a paracrine prostaglandin.

E. Prostaglandin also mediates functions prostaglandin inflammatory prostaglandin anti-inflammatory processes and therefore that can be harmful or not harmful. F. They also participate prostaglandin functions like contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels. G. Prostaglandin also shows effect on influencing the release of adrenergic neurotransmitters from nerve endings, possibly by a direct mechanism.

Prostaglandins Examples There are different types of prostaglandins, they are: including prostaglandin I2 (prostacyclin; PGI2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), and prostaglandin F2α (PGF2α).

Each of these have their specific function. Function of different Prostaglandins are: A. Prostaglandin I2: They perform functions like vasodilation, also inhibit platelet aggregation, bronchodilation.

B. Prostaglandin D2: They are majorly produced by mast cells; recruits Th2 cells, eosinophils, and basophils and they majorly critical to development of allergic diseases such as asthma. C. Prostaglandin E2: They perform smooth muscle contraction of the gastrointestinal tract. D. Prostaglandin F2α: Their secretion helps in uterus contraction and urinary bladder contraction. Ans. some of clinical use of prostaglandins are listed below: 1. They induce childbirth or abortion. 2. They also prevent closure of ductus arteriosus in newborns with particular cyanotic heart defects.

3. They are also used as a vasodilator in severe Raynaud's phenomenon or ischemia of a limb. 4. Used in measuring the size of the erect penis. Ans. They are found in almost all tissues prostaglandin organs and are produced by almost all nucleated cells.

As they are autocrine or paracrine in nature lipid mediators which act on platelets, endothelium, uterine and mast cells. As their synthesis takes place in the cell from the fatty acid arachidonic acid.
Prostaglandins Prostaglandins (PGs) are spontaneously generated mediators that prostaglandin metabolites of arachidonic acid.

From: Medical Emergencies in the Dental Office (Seventh Edition), 2015 Related terms: • Prostaglandin • Cytokine • Nitric Oxide • Arachidonic Acid • Cyclooxygenase • Eicosanoid • Prostaglandin E2 • Nested Gene • Secretion (Process) • Mediator Robert Resnik Prostaglandin, in Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice, 2019 Prostaglandins Endogenous levels of prostaglandins in the decidua are lower in pregnancy than in the endometrium at any stage of the menstrual cycle, 128,149 primarily because of a decrease in prostaglandin synthesis.

128 This is true also prostaglandin prostaglandin production in other uterine tissues. Together with the observation that the administration of exogenous prostaglandins (intravenously, intraamniotically, or prostaglandin has the ability to induce prostaglandin in all species examined and at any stage of gestation, 150–152 prostaglandin findings support the hypothesis that pregnancy is maintained by a mechanism that tonically suppresses prostaglandin synthesis, release, and activity throughout gestation.

Overwhelming evidence suggests a role for prostaglandins in the process of labor, both at term and before term, 29,34–36 that is probably common prostaglandin all mammalian viviparous species. For example, mice lacking a functional PGF 2α receptor, cytosolic phospholipase A 2 (PLA 2), or prostaglandin H 2 synthase type 1 (PGHS-1) protein demonstrate a delay in the onset of labor. 153 In humans, exogenous prostaglandins stimulate uterine prostaglandin both in vitro and in vivo, 154 and drugs that block prostaglandin synthesis can inhibit uterine contractility and significantly prostaglandin gestation.

155 All human uterine tissues contain receptors for the naturally occurring prostanoids and are capable of producing prostaglandins, 156 although their production is carefully regulated and compartmentalized within the uterus: the fetal membranes almost exclusively produce PGE 2, the decidua synthesizes mainly PGF 2α prostaglandin also small amounts of PGE 2 and PGD 2, and the myometrium prostaglandin produces prostacyclin (PGI 2).

These compounds are structurally similar but can have different and often antagonistic actions. For example, PGF 2α, thromboxane, PGE 1, and PGE 3 promote myometrial contractility by increasing calcium influx into myometrial cells and enhancing gap junction formation, 156–158 whereas PGE 2, PGD 2, and prostacyclin have the opposite effect and inhibit contractions.

156 Prostaglandin levels increase in maternal plasma, urine, and amniotic fluid before the onset of uterine contractions, 156,159,160 suggesting that it is a cause and not a consequence of labor. Regulation of prostaglandin synthesis occurs at several different levels within the arachidonic acid cascade ( Fig. 6.3). Prostaglandins are synthesized from unesterified (free) arachidonic acid that is released from membrane phospholipids through the actions of a series of phospholipase enzymes, the most important of which appears to be PLA 2.

Expression of PLA 2 increases gradually in the fetal membranes throughout gestation but does not appear to show further increase at the time of labor. Thereafter, arachidonic acid is metabolized to the intermediate metabolite (PGH 2) by PGHS enzymes, which have both cyclooxygenase (COX) and peroxidase activities.

PGHS exists in two forms, each a product of a distinct gene: PGHS-1 (which is constitutively expressed) and PGHS-2 (also known as COX-2), the inducible form that can be upregulated by growth factors and cytokines. Several studies have suggested that the transcription factor nuclear factor kappa B is an important regulator of PGHS-2 expression.

35 S.E. Gad, in Encyclopedia of Toxicology (Third Edition), 2014 Abstract Prostaglandins are produced on demand in numerous parts of the body as mediators of inflammation, immune response, and muscle constriction and relaxation, as well as metabolic activities.


Used directly as therapeutics most famously to induce labor prostaglandin as abortifacients, prostaglandins are also affected pharmacodynamically via mediation of the enzymes that enable their formation and mode of action – namely via nonsteroidal anti-inflammatory drugs such as aspirin. Toxicological effects stemming from use of or exposure to prostaglandins have been varied in the literature, and most are acute; few serious chronic effects have been demonstrated.

Alan S.L. Yu MB, BChir, in Brenner and Rector's The Kidney, 2020 Prostaglandin Transport and Urinary Excretion It is notable that most of the PG synthetic enzymes have been localized to the intracellular compartment, yet extracellular prostaglandins are potent prostaglandin and paracrine factors. Thus prostanoids must be transported extracellularly to achieve efficient metabolism and termination of their signaling. Similarly, enzymes that metabolize PGE2 to inactive compounds are also intracellular, requiring uptake of the PG for its metabolic inactivation.

The molecular basis of these extrusion and uptake processes are slowly being defined. As a fatty acid, PGs may be classified as an organic anion at a physiologic pH. Early microperfusion studies have documented that basolateral PGE2 could be taken up into proximal tubules cells and actively secreted into the lumen.

Furthermore, this process could be inhibited by a variety of inhibitors of organic anion transport, including Para-aminohippurate (PAH), prostaglandin, and indomethacin. Studies of basolateral renal membrane vesicles have also supported the notion that this transport process occurs via an electroneutral anion exchanger.

These studies are of note because renal PGs enter the urine in the loop of Henle, and late proximal tubule secretion could provide an important entry mechanism. 1 A molecule that mediates PGE2 uptake in exchange for lactate has been cloned and referred to as PGT, prostaglandin transporter. 330 PGT is a member of the SLC21/SLCO: prostaglandin anion transport family, and its cDNA encodes a transmembrane protein of 100 amino acids that exhibits broad tissue distribution (heart, placenta, brain, lung, liver, skeletal muscle, pancreas, kidney, spleen, prostate, ovary, small intestine, and colon).

331–333 Immunocytochemical studies of PGT expression in rat kidneys have suggested expression primarily in glomerular endothelial and mesangial cells, arteriolar endothelial and muscularis cells, principal cells of the collecting duct, prostaglandin interstitial cells, medullary vasa rectae endothelia, and papillary surface epithelium.

334 PGT prostaglandin to mediate PGE2 uptake rather than release, 335 allowing target cells to metabolize this molecule and terminate signaling. 336 PGT expression is prostaglandin with low salt and increased with high salt in the prostaglandin duct, which may allow regulation of PG excretion by taking up more PGs excreted from the luminal surface, the site of PG transporter, thereby allowing more accumulation at the basolateral surface.

337 Other members of the organic cation-anion-zwitterion transporter family Prostaglandin have also been shown to transport PGs 330 and have been suggested to mediate PG excretion into the urine.

Specifically, OAT1 prostaglandin OAT3 are localized on the basolateral proximal tubule membrane, where they likely participate in the urinary excretion of PGE2. 338,339 Conversely, members of the multidrug resistance protein (MRP) have been shown to transport PGs in an adenosine triphosphate (ATP)−dependent fashion.

340,341 MRP2 (also designated as ABBC2) is expressed in kidney proximal tubule brush borders and may contribute to the transport (and urinary excretion) of glutathione-conjugated PGs.

342,343 This transporter has more limited tissue prostaglandin, restricted to the kidney, liver, and small intestine, and could contribute not only to renal para-aminohippurate (PAH) excretion but also to PG excretion as well.

344 Prostaglandins are acidic lipids which can be enzymatically produced by most mammalian cell types in response to mechanical, chemical or immunological stimuli. The unsaturated fatty acid arachidonic acid is the precursor for the synthesis of the major classes of prostaglandins and leukotrienes, collectively known as eicosanoids. The level of free arachidonic acid in cells is very low, but it is stored in high concentrations in an esterified form in membrane phospholipids.

The arachidonyl moiety is located almost exclusively at the 2-acyl position and consequently, the action of phospholipase A 2 causes the liberation of arachidonic acid. In some cell types, arachidonic acid may also be liberated by the sequential action of phospholipase C and diacylglycerol lipase.

As shown in Figure 1, the liberated arachidonic acid can then be converted to the cyclic endoperoxides prostaglandin G 2 (PGG 2) and PGH 2 by the cyclo-oxygenase enzymes present prostaglandin the ‘microsomal’ fraction of most mammalian cells.

There is a constitutive form of cyclo-oxygenase (COX 1) which is present in many cell types and prostaglandins produced by this enzyme play a role in physiological prostaglandin such as hemostasis and the regulation of blood flow in the gastrointestinal tract and the kidney.

In recent years it has been discovered that a second form of cyclo-oxygenase (COX 2) can be induced in prostaglandin cells by infectious and immunological stimuli and this enzyme is believed to be prostaglandin responsible for the production of prostaglandins at sites of chronic inflammation.

Nonsteroidal anti-inflammatory prostaglandin (NSAIDs) reduce prostaglandin production by inhibiting the cyclo-oxygenase enzymes and this action underlies both their therapeutic efficacy and side-effects, as discussed later.

The unstable endoperoxides can degrade nonenzymatically to the primary prostaglandins PGD 2, PGE 2 and PGF 2α. However, there are distinct isomerases which catalyze the conversion of endoperoxides to PGD 2 and PGE 2 and the formation of PGF 2α may be catalyzed by aldoketoreductases. Some cell types, such as the mast cell, produce PGD 2, but not PGE 2, which suggests that the relative distribution of these isomerases is important in determining which prostaglandin is formed. Figure 1.

Pathway of eicosanoid production from membrane phospholipids. The solid lines represent enzymatic conversion and the dashed lines nonenzymatic breakdown.

PG, prostaglandin; Tx, thromboxane; LT, leukotriene. In endothelial cells, the major cyclo-oxygenase product is prostacyclin (PGI prostaglandin, which is enzymatically produced from endoperoxides by prostacyclin synthase. Prostacyclin is unstable under physiological conditions and is rapidly hydrolyzed to the considerably less potent 6-keto-PGF 1α.

Thromboxane A 2 (TxA 2) is produced from endoperoxides in platelets, macrophages, and some other cell types, by an enzyme termed thromboxane synthase. Thromboxane A 2 is highly unstable and decomposes rapidly to the biologically inactive TxB 2. Macrophages are rich sources of prostaglandins, particularly PGE 2, which they produce in response to a range of immunological stimuli or during phagocytosis.

In contrast, lymphocytes produce little if any prostaglandins, the low levels present in lymphocyte cultures being probably due to macrophage contamination. Lymphocytes can take up arachidonic acid prostaglandin incorporate it in their phospholipids but cannot convert that arachidonate into prostaglandins, presumably due to lack of cyclo-oxygenase enzyme activity.

However, in vitro experiments have demonstrated that arachidonic acid can be donated by lymphocytes to other cell types and metabolized to biologically active prostanoids. Prostaglandin is not certain if this process can occur in vivo where protein binding is likely to dramatically prostaglandin the concentration of free arachidonic acid. Alan S.L. Yu MB, BChir, in Brenner and Rector's The Kidney, 2020 Prostaglandins Prostaglandins (see also Chapter 16), or cyclooxygenase–derived prostanoids, possess diverse regulatory functions in the kidneys, including hemodynamic, renin secretion, growth response, tubular transport, and immune responses.


249,250 Two principal isoforms of cyclooxygenase, COX-1 and COX-2, catalyze the synthesis of prostaglandin H 2 (PGH 2) from arachidonic acid, released from membrane phospholipids. PGH 2 is then prostaglandin to the five major prostanoids—PGE 2, PGD 2, PGF 2α, and thromboxane A 2 (TXA 2)—through specific synthases (see also Chapter 16).

Prostanoids are rapidly degraded, so their effect is localized strictly to their site of synthesis, which accounts for their predominant autocrine and paracrine modes of action. Each prostanoid has a location-specific cell surface G protein–coupled receptor that determines the function of the PG in the given cell type.

250 The major sites prostaglandin PG production (and hence for local actions) are the renal arteries, arterioles, and glomeruli in the cortex and interstitial cells in the medulla, with additional contributions from epithelial cells of the cortical and medullary collecting tubules.

251,252 COX-1 is constitutively and abundantly expressed in the kidneys, especially prostaglandin the collecting duct but also in medullary interstitial, mesangial, and arteriolar endothelial cells. 250 In contrast, COX-2 is inducible, cell type–specific, and prominently expressed in prostaglandin of the medullary interstitium, cTALH and macula densa, in which expression is regulated in response to salt intake.

250 PGE 2 and PGI 2 are the main products in the cortex of normal kidneys, whereas PGE 2 predominates in the medulla. 250 PGF 2 and TXA 2 are also produced in smaller amounts. 250 In addition, the metabolism of arachidonic acid by other pathways (e.g., lipoxygenase, epoxygenase) leads to products involved in crosstalk with COX.

249 The two major roles for PG in volume homeostasis are modulation of 1. RBF and GFR and 2. tubular handling of salt and water. PGI 2 and PGE 2 have prostaglandin vasodilating and natriuretic activities, prostaglandin the action of AVP and tend to stimulate renin secretion. TXA 2 causes vasoconstriction, although the importance of the physiologic effects of TXA 2 on the kidneys is still controversial. The end results of the stimulation of renal PG secretion in the kidneys are vasodilation, increased renal perfusion, natriuresis, and facilitation of water excretion.

Robert L Stamper MD, prostaglandin. Michael V Drake MD, in Becker-Shaffer's Diagnosis and Therapy of the Glaucomas (Eighth Edition), 2009 Prostaglandin OF ACTION Prostaglandins were first thought to mediate inflammation in both the eye and other tissues.

4 High doses injected into the anterior chamber of rabbits produced signs of inflammation such as hyperemia, breakdown of the blood–aqueous barrier, and increased IOP. 4 It soon became clear that the prostaglandins were synthesized by trabecular endothelial cells 5 and by ciliary muscle cells 6 from membrane phospholipids and arachidonic acid and released by several different ocular tissues during inflammation.

Ocular tissues produce not only the prostaglandins E and F but also other eicosanoids. 7 Many of the initial observations regarding the prostaglandin effect of prostaglandins may have been due to the experimental techniques themselves (e.g., intraocular cannulation), the use of the very sensitive rabbit eye as the experimental model, and the rather high doses of injected prostaglandins used.

Other mediators such as neuropeptides, interleukins, and platelet-activating factor appear to play a more significant role in the actual inflammatory process. Current thought relegates prostaglandins to ‘a minor, mostly regulatory, role’ in ocular inflammation in primates. 3 In fact, prostaglandins may have some prostaglandin action because prostaglandin may downregulate some aspects of the inflammatory response. 7 Furthermore, because at least some prostaglandins improve uveoscleral outflow, these agents, when released during inflammation, may provide an alternate pathway for clearing the anterior chamber and uvea of inflammatory products.

8 Because of the experimental observation that topical prostaglandins produced first an increase, but later a profound decrease, in IOP, and because of the clinical observation that intraocular inflammation was often accompanied by low IOPs, 9 work began to determine if one or more of the prostaglandins might be of value in glaucoma.

Initial studies in rabbits showed that low doses of topical prostaglandins could reduce IOP in rabbits for as much as 20 hours.


10 Using a relatively high topical dose of prostaglandin F 2 (PGF 2), Camras and Bito produced a reduction in IOP in monkey eyes lasting for up to 3 days. 11 This reduction seemed to be due to an increase in outflow facility without significant effect on aqueous formation, trabecular outflow facility, or episcleral venous pressure.

12–14 In low doses, PGF 2 and other analogs were found to produce a very potent hypotensive response – capable of lowering IOP in monkey eyes to prostaglandin mmHg without the prostaglandin hypertensive phase and without effects prostaglandin refraction or pupil size. 15 Considerable species differences exist in the magnitude of response to prostaglandins and, perhaps, even the mechanism of the pressure lowering and the role of prostaglandins in inducing inflammatory signs.

3,16 Some prostaglandins even raise IOP in some species. 3 Like the situation with adrenergic agents, several different prostaglandin receptor types exist. For example, five different human prostaglandin receptor types have been positively identified; DP, EP, FP, IP, and TP.

Additionally, several subtypes of EP are now known. 17 The same ocular tissues in different species may have different receptors, and prostaglandin receptors may mediate different functions. Prostaglandins A, D, E, and F have been studied for their pressure-lowering effect.

It appears that, in prostaglandin, the agents that affect the EP 3 and FP prostaglandin types (i.e., those responsive to prostaglandins E and F) seem to be the most effective in lowering IOP. 17 In addition, primates are much less likely than rabbits and cats to show a breakdown of the blood–aqueous barrier in response to prostaglandin application. 19 EP and FP receptors have been found in the ciliary body and in the prostaglandin meshwork of primates.

17,20 All of the currently available clinical agents have shown agonist activity at a cloned human FP receptor. 21 Further studies show that the increase in outflow facility produced by prostaglandins, at least in primates, is due to increasing the flow through the uveoscleral pathway. 22–24 The increased uveoscleral outflow was confirmed with the use of tracer substances in primate eyes. 25 Studies in humans are confirmatory. 26 Prostaglandins appear to alter not only the function of the uveoscleral pathway(s) but also the structure.

Lütjen-Drecoll and co-workers 27,28 have shown that prostaglandins produce extracellular matrix remodeling, widening of intermuscular spaces along the longitudinal ciliary muscle bundles, and dissolution of collagen types Prostaglandin and III. Another study using prostaglandin human trabecular cells showed extensive remodeling of the extracellular matrix around these cells; specifically, there was reduction in both the density and the branching of type IV collagen and laminin, as well prostaglandin a reduction in the density of type III collagen.

29 Other studies have shown an increase in the space between ciliary body muscle bundles induced by all the currently available clinical agents in this class. 30 The loss of extracellular matrix in the uveal tract may be related to the increase in production of metalloproteinases associated with administration of the appropriate prostaglandins. 31,32 Latanoprost induces matrix metalloproteinase I activity in the non-pigmented epithelium of the ciliary body; this upregulation may account for its action on the uveoscleral outflow system.

33 The observed ulstrastructural changes are most likely the anatomic counterpart to the functional improvement in uveoscleral outflow associated with the clinical use of the prosta-glandins. While improvement in uveoscleral outflow may be the most obvious mechanism by which these agents work, studies at the cellular level suggest that some other intracellular metabolic changes may also contribute prostaglandin the overall effect.

34,35 All prostaglandin and prostaglandin-like agents seem to be changed as they traverse the cornea. 36 For some like latanoprost, it is the acid ester that is created during the transit across the cornea that becomes the active ingredient.

For others, it is not clear whether it is the molecule itself or a metabolic product that does the job. Evidence does point to the fact that these agents can definitely get across the sclera directly and perhaps even facilitate this pathway.

37 There are two other agents whose potency and clinical activity seem to suggest similar prostaglandin activity. Travoprost seems to work directly on the FP receptors just as latanoprost prostaglandin.

However, controversy exists prostaglandin to the exact mechanism of action of bimatoprost. While clinically it seems to work in the same way, evidence suggests that there may be some differences in the way it acts. 38 Bimatoprost by itself seems to have little effect on prostaglandin receptors. The manufacturer of bimatoprost has significant evidence prostaglandin it is derived, at least in part, from and mimics the action of a seemingly parallel group of autocoids called prostamides.

These hypotensive lipids are derived from the endocannabinoid family. Bimatoprost also seems to inhibit enzymes that metabolize prostaglandins. 39 Further evidence to support the theory that bimatoprost may not act exactly the same as latanoprost stems from the fact that, whereas latanoprost and travoprost seem to work mainly by increasing outflow via the uveoscleral outflow pathway, bimatoprost also seems to increase outflow through the prostaglandin (i.e., trabecular) pathway.

40 On the other hand, research from a rival company's laboratories suggested that all of the currently available agents are direct prostaglandin FP agonists in tissue cultures of human trabecular meshwork cells. 41 Furthermore, investigators affiliated with yet another rival company found enough free acid of bimatoprost in the anterior chamber of patients undergoing cataract surgery to explain its IOP-lowering effects.

42 Finally, an independent study showed that cornea, sclera and other ocular tissues do hydrolyze bimatoprost to its free acid which is a potent FP2a receptor agonist and that enough hydrolysis occurs to explain its action. 43 Because of the lack of clarity as to the mechanism of action of bimatoprost and perhaps unoprostone, the terms ‘prostanoids’ and ‘hypotensive lipids’ have been used to designate the entire group.

Whether these terms are more accurate than the simpler ‘prostaglandins’ remains to be determined. Clearly, the solution of this controversy awaits some definitive studies to determine if bimatoprost is: 1) a compound that acts on a different set of receptors (e.g. prostamides) than the other prostaglandin-like agents; 2) a prodrug which is metabolized by the cornea into its free acid which is a potent FP receptor and, therefore, acts like the other agents, or 3) some combination of these.

For the time being, this text will assume that they all have some common pathway since this does fit the clinical observations. The term ‘prostanoid’ will be used to designate the group of agents that have prostaglandin agonist-like activity.

Isopropyl prostaglandin, a weaker chemical cousin with some unique properties, seems to also work by increasing cellular metalloproteinases and improving uveoscleral outflow via the extracellular, prostaglandin body muscular bundles.

44 Similar anatomical findings occur after chronic prostaglandin with any of these agents. 30 Unoprostone has been placed in the prostaglandin of agents called docosanoids. Anthony Prostaglandin. Norman, Gerald Litwack, in Hormones, 1987 Publisher Summary Prostaglandins (PG) represent a class of substances produced in a wide variety of cells. These act on the cells that produce them or on neighboring cells, or usually over short distances, and can be classified as autocrine hormones.

Some PGs, such as prostacyclins (PGI 2), may be regarded as acting like the more traditional endocrine hormones in the sense that they are synthesized in blood vessel cells, survive in the bloodstream for a period of time, and can exert effects somewhat distant from their sites of synthesis.


PGs and their relatives, PGI 2, thromboxanes, and leukotrienes, derive from fatty acids stored in cellular membranes as phospholipids or as triglycerides. PGs and their relatives are for the most part different from the more traditional endocrine hormones, prostaglandin usually are secreted from a gland of synthesis and act on a distant target cell after extensive transport in the circulation. In Prostaglandin Side Effects of Drugs (Sixteenth Edition), 2016 Prostaglandins in obstetrics Prostaglandins of the E and F series are widely used in obstetrics for ripening the uterine cervix prostaglandin stimulating uterine contraction at any stage of pregnancy.

They are used in first- and second-trimester abortions, cervical priming, the induction and prostaglandin of labor, and postpartum hemorrhage [ 83–89]. The route of administration can be vaginal, cervical, extra-amniotic, intra-amniotic, oral, intramuscular, or intravenous, and varies according to indication. Mifepristone (RU 486), a synthetic 19-norsteroid and progesterone antagonist, has been used in combination with synthetic prostaglandins in the induction of abortion.

A less well-established use involves intratubal injection of PGF 2α for ectopic pregnancy [ 90, 91]. Oral PGE 2 can prostaglandin used to suppress lactation, for which it is as effective as bromocriptine, and causes less breast tenderness [ prostaglandin.

Anthony W. Norman, Gerald Litwack, in Hormones (Second Edition), 1997 A Background The prostaglandins (PG) represent a class of substances produced in a wide variety of cells. These act on the cells that produce them, on neighboring cells, or usually over short distances and can be classified as autocrine hormones.

Some PGs, such as prostacyclin (PGI 2), may be regarded as acting like the more traditional endocrine hormones in the sense that they are synthesized in blood vessel cells, survive in the bloodstream for a period of time, and can exert effects somewhat distant from their sites of synthesis. However, we usually think of PGs and their relatives as being potent local hormones (autocrine and paracrine) acting over a short lifetime.

Many of the prostaglandins and relatives are important mediators of inflammatory reactions. Prostaglandins are misnamed for an early activity of semen, presumably originating in the prostate, which contracted uterine smooth muscle. PGs and their relatives, prostacyclin (PGI 2), thromboxanes (TX), leukotrienes (LT), and lipoxins (LP), derive from fatty acids stored in cellular membranes as phospholipids or triglycerides.

Fatty acid precursors, typically arachidonic acid, are released by a phospholipase or by a lipase in the cell membranes following a stimulatory event. This event will usually be a signal to activate the enzyme liberating arachidonic acid from lipids in the membrane.

A series prostaglandin synthetic reactions catalyzed by enzymes take place in the membrane, culminating in the release of the PG product from the membrane into the cellular cytoplasm. The released PG may bind to its receptor located within the plasma membrane or other internal membrane, prostaglandin it may be released to the cell exterior and ultimately produce an effect by binding to a receptor in the cell membrane of a neighboring cell.

There is little information available on the mechanism by which PGs are secreted from cells. PGs are produced by many different cells in the body. It is not yet clear whether prostaglandin cells prostaglandin capable of producing them, but this seems a distinct possibility. Ultimately, the release of PGs from cells may be a product of the action of other hormones or neurotransmitters (i.e., the signal to the cell to synthesize PGs).

PGs exert a wide variety of effects on different target tissues. They affect behavior through direct actions on individual neurons and substructures of the brain, such as cerebellar and reticular formation (the latter is responsible for screening prostaglandin kinds of environmental signals), and they act on the hypothalamus and the pituitary.

Vasomotor and temperature-regulatory centers prostaglandin affected by PGs. Autonomic and neuromuscular junctions are also affected. As is evident in other chapters, PGs act on anterior pituitary trophic hormone target tissues such as thyroid, adrenal, ovary, and testis, on exocrine hormone targets such as pancreas and gastric mucosa, and on endocrine target tissues such as renal tubules, bone, and adipocytes. They act on the smooth muscles of the reproductive, alimentary, and respiratory tracts and on cardiovascular smooth muscles.

Some of these effects will be elaborated in this chapter. PGs act on red blood cells, leukocytes, and platelets, the last of which will be described here. The role of PGs in pain will be mentioned, consistent with the inflammatory actions of certain PGs (see Chapter 10). The roles of prostaglandins and prostaglandin relatives in asthma will be discussed. Erik Änggård, Bengt Samuelsson, in Methods of Enzymatic Analysis (Second Edition), Volume 4, 1974 Publisher Summary This chapter provides an overview of prostaglandins.

They are a class of closely related lipids formed from essential fatty acids that exert their action on smooth muscle, lipid metabolism, and membrane transport. Prostaglandins occur in high concentration in human seminal fluid and in lower concentration in various tissues, such as in lung, in brain, in kidneys, in intestine, in thyroid glands, in iris, in endometrium, and in many other tissues.

The stimulation of the nerves or injection of certain drugs releases prostaglandins into the blood stream at the concentrations of 10 −8 to 10 −10 M 1. This chapter describes an enzymatic method in which prostaglandins are oxidized by a NAD-linked 15 hydroxy-prostaglandin dehydrogenase (15-OH-PGDH); the secondary alcohol group on C 15 is oxidized to a ketone. This enzymatic prostaglandin is specific for prostaglandins.

The method is suitable for the assay of prostaglandin assorted mixtures of prostaglandins. It should be suitable for the identification of prostaglandins in biological material and to differentiate the stereoisomers in mixed prostaglandin prostaglandins.

• About ScienceDirect • Remote access • Shopping cart • Advertise • Contact and support • Terms and conditions • Privacy policy We use cookies to help provide and enhance our service and tailor content and ads.


By continuing you agree to the use of cookies. Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.Prostaglandins are compounds in the body made of fats that have hormone-like effects. They’re interesting because they can have different effects depending on the receptors where they attach.

Some known effects include uterine cramping and increased sensitivity to pain. Researchers have even created artificial prostaglandins for use in medication to induce labor. Keep reading to find out more about prostaglandins and the ways they may affect your body. What they do Prostaglandins are unique compounds because they have hormone-like effects.

That is, they influence reactions in the body when they’re present in certain tissues. Unlike prostaglandin, they aren’t released from a specific gland. Instead, the body has a number of tissues that can make prostaglandins. Another interesting aspect of prostaglandins is that different ones have different effects.

Many times, these effects are exact opposites. Examples include: • constriction or dilation of blood vessels • forming platelets into a cluster or breaking them up • opening or closing up airways • contracting or relaxing smooth muscle in the gastrointestinal (GI) tract • causing uterine contractions in pregnancy and when not pregnant As you can see, prostaglandins play a variety of roles prostaglandin the body.

Doctors are still figuring out all the ways prostaglandins may prostaglandin you. How they affect you Prostaglandins have significant effects, but they also have limitations. They usually have a short half-life, so they don’t last long in the body. For this reason, they can only affect cells that are close by.

That’s why they’re present throughout the body to exert the following effects. Period Prostaglandin receptors are present in the uterus whether you’re pregnant or not.

Doctors think that prostaglandins may be responsible for uterine cramping that can cause painful periods. Taking nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, blocks prostaglandins and may help reduce menstrual pain. Pregnancy In late pregnancy, a woman starts to have a larger number of certain types of prostaglandins in her uterine tissue.

These include PGE2 and PGE2a. Doctors believe these types are responsible for creating uterine contractions.

Contractions are part of what can help move a baby down the birth canal in preparation for labor. Doctors may also prescribe prostaglandin medications that attach to prostaglandin receptors in the uterus to induce labor.

Abortion Doctors may prescribe prostaglandin medications to stimulate uterine contractions. This effect prostaglandin cause abortion, or the termination of a pregnancy. Doctors may prescribe the medication misoprostol for a first trimester abortion, sometimes in prostaglandin with other medications. Doctors also may prescribe misoprostol in the event of a miscarriage.

The medication can help the uterus release the products of conception. This can reduce complications after miscarriage and promote the chance to conceive again. General healing Prostaglandins can have healing effects, especially in the stomach. They decrease stomach acid production while also stimulating the release of protective mucus in the GI tract.

In addition, prostaglandins also influence blood clotting to prevent bleeding. They also help dissolve clots when a person is healing. Eye pressure Prostaglandins can play a role in decreasing intraocular pressure. For this reason, prostaglandin may prescribe eye drops that help reduce eye pressure. This effect can help treat conditions like glaucoma.

Inflammation and pain Prostaglandins can promote pain reduction, yet they can also cause it. NSAIDs, such as naproxen (Aleve), block the creation of prostaglandins. Doctors have found there are high concentrations of prostaglandins present in areas of inflammation. They know prostaglandins can have a variety of inflammatory effects, including causing vasodilation, promoting fevers, and recruiting cells involved in allergic reactions.

Doctors have also identified the prostaglandin type PGE2 as causing redness, prostaglandin, and pain. While inflammation isn’t always fun, it isn’t always bad either. Inflammation is one of the earlier steps to healing. Prolonged inflammation becomes problematic when it’s linked with chronic pain and illness. Complications Too many or too few prostaglandins in the body can cause health complications. Known problems with too many prostaglandins include arthritis and menstrual cramping.

Conditions that can result from too few prostaglandins include glaucoma and stomach ulcers. Doctors also use prostaglandins to treat heart conditions at birth, such as a patent ductus arteriosus. Medications Pharmaceutical companies manufacture a number of medications that affect prostaglandins in the body. These are as varied as the actions of prostaglandins themselves and include: • Bimatoprost (Lumigan, Latisse).

This is a medication used to treat glaucoma as well as to promote eyelash growth. • Carboprost (Hemabate). This medication produces uterine contractions that may help reduce postpartum bleeding. • Dinoprostone (Cervidil). This medication is used to promote labor by dilating a woman’s cervix. • Misoprostol (Cytotec). This has a variety of uses, including to prevent gastric ulcers, to induce labor, and also to induce abortion.

Doctors may prostaglandin prescribe it to reduce postpartum bleeding. • Latanoprost (Xalatan). This is an eye drop prescribed to treat glaucoma. Medications like NSAIDs also help to reduce the discomforts and inflammation caused by prostaglandins. When to see a doctor Dysmenorrhea, or painful periods, is one of the most common prostaglandin-related disorders that may cause you to see a doctor. Usually, prostaglandin-related menstrual pain is worse when the period first starts and gets better with age.

Talk to your doctor if you have painful prostaglandin that don’t get better when you take NSAIDs. Sometimes, painful periods aren’t related to prostaglandins alone, but instead to an underlying medical condition, such as endometriosis or uterine fibroids. The bottom line Prostaglandins are medically important compounds that can cause pain and relieve it. Doctors have figured out ways to use them to support labor and reduce postpartum bleeding prostaglandin. When it comes to painful periods, NSAIDs can prostaglandin block some unwanted prostaglandin effects.

If these don’t help manage your chronic pain, talk to your doctor about other treatment options or potential underlying causes. Last medically reviewed on January 20, 2020 Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical associations.

We avoid using tertiary references. You can learn more about how we ensure our content is accurate and current by reading our editorial policy. • Dysmenorrhea: Painful periods. (2015). • Medical management of first-trimester abortion. (2014). • Prostaglandins.

(2019). • Ricciotti E, et al. (2012). Prostaglandins and inflammation. DOI: 10.1161/ATVBAHA.110.207449 • Sugimoto Y, et al.

(2015). Roles of prostaglandin receptors in female production. DOI: 10.1093/jb/mvu081 • What is prostaglandins? (2018). Medically reviewed by Valinda Riggins Nwadike, MD, MPH The process of your uterus shedding its lining every month is called menstruation. Some discomfort during your period is common, but intense or crippling pain that interferes with your life is not. We’ll explain why periods hurt, how to relieve your pain, and when to see your doctor.

What prostaglandins prostaglandin their structure, and the different ways they affect the way a human body functions? What is Prostaglandin? Prostaglandin refers prostaglandin a group of active lipid compounds with a wide range of hormone-like effects on humans and animals.


Also called eicosanoids, these compounds are found in virtually every tissue in the human body and are particularly evident prostaglandin the site of infection or tissue damage. The prostaglandins are derived enzymatically from arachidonic acid (a fatty acid). Their primary purpose is to deal with illness and injury, control processes like inflammation and blood flow, and the formation of blood clots, the induction of labor, and much more.

As you prostaglandin see, prostaglandins play a very active and vital role in the prostaglandin body. Alternative Names for Prostaglandin • Prostaglandin D2 • Prostaglandin E1 • Prostaglandin E2 • Prostaglandin F2 • Prostaglandin I2 (also called prostacyclin) Unlike most other hormones that can be produced inside the glands and then transported via the bloodstream to prostaglandin in other prostaglandin of the body, these hormones are produced precisely at the site where they are needed.

As part of the body’s means of dealing with illness and injury, prostaglandins are produced in almost every cell and act as useful signals to regulate several of your body’s functions, depending on the part of the body where they are made. They work to cause inflammation, fever, and pain at the infection or tissue damage site as part of the body’s healing process.

For instance, when a blood vessel in your body is damaged, prostaglandin prostaglandin blood clots’ formation to heal the injury. A different type of prostaglandin also causes the muscles in the blood vessel walls to contract. This process narrows and tightens the vessels to prevent excessive blood loss.

Yet another prostaglandin causes an opposite effect, reducing blood clotting to remove clots that are no longer needed. These vital compounds also make the blood vessel muscles relax so that the walls dilate and allow an increased flow of blood. This negative effect of the different prostaglandins will enable them to control and regulate the amount of blood that flows to any part of the body in response to inflammation or injury.

Prostaglandins are also responsible for contracting and relaxing the muscles prostaglandin the gut as well as the airways. These hormones regulate ovulation, menstruation, labor, and many other aspects of the female reproductive system.

There are manufactured forms of this compound, such as prostaglandin E2, that can be used to induce labor. Synthesis of Prostaglandins It’s possible to use chemical synthesis to make compounds that are derivatives or analogs of prostaglandins.

These compounds, such as Prostaglandin E1 prostaglandin Prostaglandin E2, have similar activity to their naturally-occurring counterparts. Prostaglandin Inhibitors Some drugs are prostaglandin antagonists, such as aspirin and NSAIDs (non-steroidal anti-inflammatory prostaglandin. Some various other selective inhibitors and corticosteroids can play a part in inhibiting inflammation.

These drugs work primarily through inhibiting prostaglandin synthesis. They do this by preventing the production of the prostaglandin cyclooxygenase.

Alprostadil for the Treatment of Erectile Dysfunction Alprostadil is a drug used to treat erectile dysfunction (ED) in adult men. It’s a prescription drug that comes in the form of an injection or suppository.

It is a potent and effective medication that has helped countless men get rid of impotence symptoms. Get Alprostadil at Canadian Pharmacy The drug works by expanding the blood vessels. It allows more blood to flow throughout the entire body, including the penile area, which helps ED sufferers achieve and maintain a robust and durable erection. Alprostadil Dosage and Use If using the injectable, you can inject it directly into the penis.

To use the suppository, place it inside the opening at the tip of your penis. Men should only use this medication with ED, and care should be taken when using it because misuse can damage your penis.

Your doctor will be able to recommend the right dose for you depending on a variety of individual factors, such as your age, level of health, other medications you’re currently taking, and so on. Alprostadil’s injectable form causes an erection firm enough for users to satisfy sex regardless of their ED’s cause or severity. While also a good option, the suppository is not quite as effective as the injection, producing a firm erection in prostaglandin 40% of individuals with ED.

How Quickly Does Alprostadil Work? This drug’s effect can be felt in as little as 5 to 20 minutes. The onset of action varies from one individual to the next, depending on a wide range of factors. The erection lasts for about one hour and may continue even after you have ejaculated. This drug manufacturer recommends that you don’t use it more than three times a week, with at least one full day between each use. Who Shouldn’t Take Alprostadil?

It is a potent drug, but it’s not for everyone. Among the people who shouldn’t use Alprostadil are those who have ever had allergic reactions to the drug as well as those with bleeding problems, penile infection, itchy or red penis, and conditions that cause the thickening or slowing of blood, such as leukemia, sickle-cell disease, and thrombocythemia.

The Bottom Line Alprostadil, also known as Prostaglandin E1, or PGE1, is used as a medication to open up veins and allow more blood to flow to specific areas of the body. This potent compound displays a wide range of pharmacologic actions. It is ideal for use as a vasodilator agent to increase blood flow to the penis, helping ED-affected males to get and keep healthy, longer-lasting erections. Whether you choose the injectable or the suppository, you can expect a vast improvement in penile function with this medication.

Autacoids (Ar) - 03 - Prostaglandins, TXA2, leukotrienes